The non thrombogeneticity is the principal advantage of the tissue bioprothesis in comparing the mechanical valves. Tissue bioprothesis don't need anticoagulants for the pervention or minimalisition of the thromboembolic complications. For this reason bioprothesis are thought to be the first choise.
Effectif orifice area is designed for the minimal resistance to the forward flow and for reaching the minimal closing volume. in such design the criteria of the bioprosthetic heart valve are realised. The effective orifice area is incised in such manner that one of the ends of the incision is 3-4 mm from the stent. Therefore the two leaflets are simply reaching one another, and the closing volume is minimalised